艾德拉尼联合奥法木单抗治疗经治慢性淋巴细胞白血病的疗效与安全性:一项开放标签随机3期试验
这项全球开放标签随机3期试验纳入261例经治复发性慢性淋巴细胞白血病患者,按2:1随机接受艾德拉尼联合奥法木单抗或奥法木单抗单药治疗。主要分析显示联合组中位无进展生存期为16.3个月,单药组为8.0个月(校正HR 0.27,95%CI 0.19-0.39,p<0.0001)。联合组3级及以上不良事件和严重感染更常见,治疗相关死亡22例,单药组6例。
要点
- 艾德拉尼联合奥法木单抗较奥法木单抗单药显著延长经治复发性慢性淋巴细胞白血病患者的无进展生存期。
- 联合组3级及以上中性粒细胞减少、腹泻和肺炎发生率高于单药组。
- 联合组严重感染和治疗相关死亡更常见,包括脓毒症和肺孢子菌肺炎。
核心结论
- 在复发性慢性淋巴细胞白血病患者中,艾德拉尼联合奥法木单抗较奥法木单抗单药获得更好的无进展生存期,包括高危患者,可能成为新的治疗选择。
研究设计与样本
- 全球、开放标签、随机、对照3期试验,纳入261例距末次治疗进展小于24个月的复发性慢性淋巴细胞白血病患者,排除对奥法木单抗难治者。
- 按复发或难治、del(17p)或TP53突变或两者兼有、IGHV突变或未突变分层,以2:1比例随机分配至艾德拉尼联合奥法木单抗组或奥法木单抗单药组。
- 联合组方案:口服艾德拉尼150 mg每日两次持续给药,联合奥法木单抗第1周静脉300 mg,随后1000 mg每周一次共7周,再每4周一次共16周;单药组奥法木单抗给药方案同联合组,但以2000 mg替代1000 mg剂量。
- 主要终点为独立评审委员会依据改良国际慢性淋巴细胞白血病工作组2008标准评估的意向治疗人群无进展生存期。
主要发现
- 主要分析时,艾德拉尼联合奥法木单抗组中位无进展生存期为16.3个月(95%CI 13.6-17.8),奥法木单抗单药组为8.0个月(95%CI 5.7-8.2),校正HR 0.27(95%CI 0.19-0.39),p<0.0001。
- 联合组最常见的3级及以上不良事件为中性粒细胞减少(59例[34%] vs 单药组14例[16%])、腹泻(34例[20%] vs 1例[1%])和肺炎(25例[14%] vs 7例[8%])。
- 单药组最常见的3级及以上不良事件为中性粒细胞减少(14例[16%])、肺炎(7例[8%])和血小板减少(6例[7%] vs 联合组19例[11%])。
- 联合组严重感染更常见,包括肺炎(联合组23例[13%] vs 单药组9例[10%])、脓毒症(11例[6%] vs 1例[1%])和肺孢子菌肺炎(8例[5%] vs 1例[1%])。
- 联合组发生22例治疗相关死亡(最常见为脓毒症、脓毒性休克、病毒性脓毒症和肺炎),单药组发生6例治疗相关死亡(最常见为进行性多灶性白质脑病和肺炎)。
关键数值与推荐
- 主要终点无进展生存期:联合组中位16.3个月(95%CI 13.6-17.8) vs 单药组8.0个月(95%CI 5.7-8.2),校正HR 0.27(95%CI 0.19-0.39),p<0.0001。
- 3级及以上中性粒细胞减少:联合组59例(34%) vs 单药组14例(16%)。
- 3级及以上腹泻:联合组34例(20%) vs 单药组1例(1%)。
- 3级及以上肺炎:联合组25例(14%) vs 单药组7例(8%)。
- 治疗相关死亡:联合组22例 vs 单药组6例。
临床怎么用
- 作者认为,艾德拉尼联合奥法木单抗在复发性慢性淋巴细胞白血病患者(包括高危患者)中较奥法木单抗单药获得更好的无进展生存期,可能代表一种新的治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Idelalisib, a selective inhibitor of PI3Kδ, is approved for the treatment of patients with relapsed chronic lymphocytic leukaemia (CLL) in combination with rituximab. We aimed to assess the efficacy and safety of idelalisib in combination with a second-generation anti-CD20 antibody, ofatumumab, in a similar patient population. METHODS: In this global, open-label, randomised, controlled phase 3 trial, we enrolled patients with relapsed CLL progressing less than 24 months from last therapy. Patients refractory to ofatumumab were excluded. Patients were stratified by relapsed versus refractory disease, presence or absence of del(17p) or TP53 mutation, or both, and IGHV mutated versus unmutated. We randomised patients in a 2:1 ratio using a web-based interactive system that generated a unique treatment code, and assigned patients to receive either idelalisib plus ofatumumab (oral idelalisib 150 mg twice daily continuously plus ofatumumab 300 mg intravenously in week 1, then 1000 mg intravenously weekly for 7 weeks, and every 4 weeks for 16 weeks) or ofatumumab alone (ofatumumab dosing as per the combination group, except 2000 mg was substituted for the 1000 mg dose). An independent review committee assessed response, including progressive disease, based on imaging using modified International Workshop on Chronic Lymphocytic Leukaemia 2008 criteria. The primary endpoint was progression-free survival assessed by an independent review committee in the intention-to-treat population. We did a primary analysis (data cutoff Jan 15, 2015) and an updated analysis (data cutoff Sept 1, 2015). This trial is registered with Clinicaltrials.gov, number NCT01659021. FINDINGS: Between Dec 17, 2012, and March 31, 2014, we enrolled 261 patients (median age 68 years [IQR 61-74], median previous therapies three [IQR 2-4]). At the primary analysis, median progression-free survival was 16·3 months (95% CI 13·6-17·8) in the idelalisib plus ofatumumab group and 8·0 months (5·7-8·2) in the ofatumumab group (adjusted hazard ratio [HR] 0·27, 95% CI 0·19-0·39, p<0·0001). The most frequent grade 3 or worse adverse events in the idelalisib plus ofatumumab group were neutropenia (59 [34%] patients vs 14 [16%] in the ofatumumab group), diarrhoea (34 [20%] vs one [1%]), and pneumonia (25 [14%] vs seven [8%]). The most frequent grade 3 or worse adverse events in the ofatumumab group were neutropenia (14 [16%]), pneumonia (seven [8%]), and thrombocytopenia (six [7%] vs 19 [11%] in the idelalisib plus ofatumumab group). Serious infections were more common in the idelalisib plus ofatumumab group and included pneumonia (23 [13%] patients in the idelalisib plus ofatumumab group vs nine [10%] in the ofatumumab group), sepsis (11 [6%] vs one [1%]), and Pneumocystis jirovecii pneumonia (eight [5%] vs one [1%]). 22 treatment-related deaths occurred in the idelalisib plus ofatumumab group (the most common being sepsis, septic shock, viral sepsis, and pneumonia). Six treatment-related deaths occurred in the ofatumumab group (the most common being progressive multifocal leukoencephalopathy and pneumonia). INTERPRETATION: The idelalisib plus ofatumumab combination resulted in better progression-free survival compared with ofatumumab alone in patients with relapsed CLL, including in those with high-risk disease, and thus might represent a new treatment alternative for this patient population. FUNDING: Gilead Sciences, Inc.
引用
- Jones JA, Robak T, Brown JR, et al. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol. 2017. PMID: 28257752. doi:10.1016/S2352-3026(17)30019-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。